{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:41:43Z","timestamp":1788309703035,"version":"build-2803163510"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T00:00:00Z","timestamp":1612224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To compare the treatment approaches and disease outcomes of children with JDM followed in two European tertiary care peadiatric rheumatology centres.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The medical notes of patients with JDM seen at Istituto Giannina Gaslini (IGG) of Genoa, Italy or Great Ormond Street Hospital (GOSH) of London, UK between January 2000 and December 2015 within 6\u2009months after disease onset and followed for at least 6\u2009months were reviewed. Demographic, clinical and therapeutic data were collected. At each visit, the caring physician was asked to rate the disease state subjectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 127 patients were included, 88 at GOSH and 39 at IGG. At 24\u2009months, the median values of muscle strength and disease activity were at the normal end of the scale and around three quarters of patients were said to have inactive disease. Also, at 2\u2009years, 38.6% and 36% of British and Italian patients, respectively, had damage. Cyclophosphamide, azathioprine, infliximab, rituximab and mycophenolate mofetil were used more frequently by UK physicians, whereas ciclosporin, intravenous immunoglobulin and hydroxychloroquine were prescribed by Italian physicians.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This study shows a significant difference in the choice of medications between pediatric rheumatologists practising in the two centres. Despite this, a high proportion of patients had inactive disease at 2\u2009years and there was a low frequency of damage: modern treatments have improved outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab089","type":"journal-article","created":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T21:02:56Z","timestamp":1611608576000},"page":"5419-5423","source":"Crossref","is-referenced-by-count":12,"title":["Comparison of treatments and outcomes of children with juvenile dermatomyositis followed at two European tertiary care referral centers"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0261-5960","authenticated-orcid":false,"given":"Giulia Camilla","family":"Varnier","sequence":"first","affiliation":[{"name":"Dipartimento di Neuroscienze Riabilitazione Oftalmologia Genetica e Scienze MaternoInfantili, Universit\u00e0 degli Studi di Genova, Genoa, Italy"},{"name":"Department of Paediatric Rheumatology, Royal Manchester Children\u2019s Hospital, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Consolaro","sequence":"additional","affiliation":[{"name":"Dipartimento di Neuroscienze Riabilitazione Oftalmologia Genetica e Scienze MaternoInfantili, Universit\u00e0 degli Studi di Genova, Genoa, Italy"},{"name":"Dipartimento Clinica Pediatrica e Reumatologia, IRCCS Istituto Giannina Gaslini, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Maillard","sequence":"additional","affiliation":[{"name":"Department of Paediatric Rheumatology, Great Ormond Street Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa","family":"Pilkington","sequence":"additional","affiliation":[{"name":"Department of Paediatric Rheumatology, Great Ormond Street Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Ravelli","sequence":"additional","affiliation":[{"name":"Dipartimento di Neuroscienze Riabilitazione Oftalmologia Genetica e Scienze MaternoInfantili, Universit\u00e0 degli Studi di Genova, Genoa, Italy"},{"name":"Dipartimento Clinica Pediatrica e Reumatologia, IRCCS Istituto Giannina Gaslini, Genoa, Italy"},{"name":"Paediatrics, Sechenov First Moscow State Medical University, Moscow, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,2,2]]},"reference":[{"key":"2021110402573734500_keab089-B1","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/S0140-6736(08)60955-1","article-title":"Juvenile dermatomyositis and other idiopathic in\ufb02ammatory myopathies of childhood","volume":"371","author":"Feldman","year":"2008","journal-title":"Lancet"},{"key":"2021110402573734500_keab089-B2","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/rheumatology\/34.8.732","article-title":"The incidence of juvenile dermatomyositis: results from a nation-wide study","volume":"34","author":"Symmons","year":"1995","journal-title":"Br J Rheumatol"},{"key":"2021110402573734500_keab089-B3","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s11926-005-0048-1","article-title":"Long-term outcomes in juvenile dermatomyositis: how did we get here and where are we going?","volume":"7","author":"Huber","year":"2005","journal-title":"Curr Rheumatol Rep"},{"key":"2021110402573734500_keab089-B4","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (\ufb01rst of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"2021110402573734500_keab089-B5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"2021110402573734500_keab089-B6","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11926-018-0726-4","article-title":"New myositis classification criteria \u2013 what we have learned since Bohan and Peter","volume":"20","author":"Leclair","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"2021110402573734500_keab089-B7","volume-title":"Muscles: testing and function","author":"Kendall","year":"1993","edition":"4th edn."},{"key":"2021110402573734500_keab089-B8","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1002\/1529-0131(199910)42:10<2213::AID-ANR25>3.0.CO;2-8","article-title":"Development of validated disease activity and damage indices for the juvenile idiopathic in\ufb02ammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function","volume":"42","author":"Lovell","year":"1999","journal-title":"Arthritis Rheum"},{"key":"2021110402573734500_keab089-B9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/art.10924","article-title":"Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence","volume":"49","author":"Bode","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2021110402573734500_keab089-B10","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/art.1780371209","article-title":"Measurement of health status in children with juvenile rheumatoid arthritis","volume":"37","author":"Singh","year":"1994","journal-title":"Arthritis Rheum"},{"key":"2021110402573734500_keab089-B11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/rheumatology\/keg427","article-title":"International consensus outcome measures for patients with idiopathic in\ufb02ammatory myopathies: development and initial validation of myositis activity and damage indices in patients with adult onset disease","volume":"43","author":"Isenberg","year":"2004","journal-title":"Rheumatology"},{"key":"2021110402573734500_keab089-B12","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/rheumatology\/kex465","article-title":"Cardiovascular and cerebrovascular comorbidities of juvenile dermatomyositis in US children:an analysis of the National Inpatient Sample","volume":"57","author":"Silverberg","year":"2018","journal-title":"Rheumatology"},{"key":"2021110402573734500_keab089-B13","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/art.40418","article-title":"Efficacy and safety of cyclophosphamide treatment in severe juvenile dermatomyositis shown by marginal structural modelling","volume":"70","author":"Deakin","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2021110402573734500_keab089-B14","first-page":"117","article-title":"Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis","volume":"29","author":"Guseinova","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"2021110402573734500_keab089-B15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/acr.20015","article-title":"Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients","volume":"62","author":"Ravelli","year":"2010","journal-title":"Arthritis Care Res"},{"key":"2021110402573734500_keab089-B16","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1002\/art.24904","article-title":"Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis using the Myositis Damage Index","volume":"60","author":"Rider","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2021110402573734500_keab089-B17","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1093\/rheumatology\/keu146","article-title":"Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool","volume":"53","author":"Sanner","year":"2014","journal-title":"Rheumatology"},{"key":"2021110402573734500_keab089-B18","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/rheumatology\/kel099","article-title":"The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland): clinical characteristics of children recruited within the first 5 yr","volume":"45","author":"McCann","year":"2006","journal-title":"Rheumatology"},{"key":"2021110402573734500_keab089-B19","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/annrheumdis-2012-201483","article-title":"The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis","volume":"72","author":"Lazarevic","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2021110402573734500_keab089-B20","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/rheumatology\/kex226","article-title":"2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria\u2014methodological aspects","volume":"56","author":"Rider","year":"2017","journal-title":"Rheumatology"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab089\/36416984\/keab089.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/11\/5419\/41073122\/keab089.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/11\/5419\/41073122\/keab089.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T02:58:19Z","timestamp":1635994699000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/11\/5419\/6126419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,2]]},"references-count":20,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,2,2]]},"published-print":{"date-parts":[[2021,11,3]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab089","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,2,2]]}}}